Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mir A. Imran | Executive Chairman | 80k | -- | 1957 |
| Mr. Talat Imran | CEO & Director | 450k | -- | 1982 |
| Mr. Svai S. Sanford | Chief Financial Officer | 416k | -- | 1970 |
| Dr. Mir Hashim | Chief Scientific Officer | 416k | -- | 1960 |
| Mr. Eric Groen | General Counsel | -- | -- | 1971 |
| Ms. Bella Vazquez | Vice President of Human Resources | -- | -- | -- |
| Ms. Kate McKinley M.B.A. | Chief Business Officer | -- | -- | 1977 |
| Ms. Arvinder Dhalla | Vice President of Clinical Development | -- | -- | -- |
Rani Therapeutics Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 140
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Corporate Governance
Upcoming Events
March 20, 2024 at 8:30 PM UTC
Rani Therapeutics Holdings, Inc. Earnings Date